---
schema_version: "secwatch.filing_event.v1"
accession: "0001588978-26-000020"
form_type: "8-K"
ticker: "PRCT"
cik: "0001588978"
company_name: "PROCEPT BioRobotics Corp"
filed_at: "2026-04-29T23:59:59+00:00"
generated_at: "2026-05-15T01:56:02.934847+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PROCEPT BioRobotics Reports Q1 2026 Revenue of $83.1M, Up 20% YoY; Net Loss Widens to $31.6M

## Summary
- Total revenue $83.1M, +20% YoY; U.S. procedures 12,200, +30% YoY.
- Sold 49 U.S. Hydros systems, ASP ~$485,000; U.S. install base 765 systems, +40% YoY.
- FDA clearance of second-generation FirstAssist AI software for Aquablation therapy.
- Full-year 2026 revenue guidance $390M-$410M, growth 27%-33%; adjusted EBITDA loss outlook $30M-$17M.
- Net loss $31.6M vs $24.7M in prior year; adjusted EBITDA loss $18.1M.

## SEC filing metadata
- accession: 0001588978-26-000020
- form_type: 8-K
- ticker: PRCT
- cik: 0001588978
- company_name: PROCEPT BioRobotics Corp
- filed_at: 2026-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1588978/000158897826000020/0001588978-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1588978/000158897826000020/prct-20260429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001588978-26-000020
- JSON: https://secwatch.observer/filing/0001588978-26-000020.json
- Plain text: https://secwatch.observer/filing/0001588978-26-000020.txt

## Key facts
- Earnings Releases
  PROCEPT BioRobotics Corp reported the quarter ended March 31, 2026 results: revenue $83.1 million, net income Net loss was $31.6 million. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2026
  - Revenue: $83.1 million
  - Net income: Net loss was $31.6 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing." Wood continued: “Aquablation® users completed approximately 12,200 U.S. procedures in the first quarter of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1588978/000158897826000020/0001588978-26-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.